Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers

Canadian Journal of Cardiology

Volumn 23, Issue 1, 2007, Pages 21-45

  Arnold, J Malcolm O ^a   Howlett, Jonathan G ^b   Dorian, Paul ^c   Ducharme, Anique ^d   Giannetti, Nadia ^e   Haddad, Haissam ^f   Heckman, George A ^g   Ignaszewski, Andrew ^h   Isaac, Debra ⁱ   Jong, Philip ^c   Liu, Peter ^c   Mann, Elizabeth ^b   McKelvie, Robert S ^g   Moe, Gordon W ^c   Parker, John D ^c   Svendsen, Anna M ^b   Tsuyuki, Ross T ^j   O'Halloran, Kelly ^g   Ross, Heather J ^c   Rao, Vivek ^c   Sequeira, Errol J ^k   White, Michel ^d   more..

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MONTREAL HEART INSTITUTE   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^g HAMILTON HEALTH SCIENCES   (Canada)

^h ST PAUL S HOSPITAL   (Canada)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j UNIVERSITY OF ALBERTA   (Canada)

^k CREDIT VALLEY HOSPITAL   (Canada)

more..

Author keywords

Acute heart failure; Comorbidities; Consensus statement; Drug therapy; Guidelines; Heart failure; Intercurrent illness; Natriuretic peptides; Prevention; Risk factors

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDRALAZINE; ISOSORBIDE DINITRATE; LISINOPRIL; METFORMIN; METOPROLOL; NEBIVOLOL; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT;

ACUTE HEART FAILURE; ANEMIA; ARTICLE; BARIATRIC SURGERY; CARDIOGENIC SHOCK; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COUNTERPULSATION; DIABETES MELLITUS; DISEASE CLASSIFICATION; EVIDENCE BASED MEDICINE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LACTIC ACIDOSIS; META ANALYSIS; MICROALBUMINURIA; OBESITY; PATIENT MONITORING; PRACTICE GUIDELINE; PROGNOSIS; RISK FACTOR; SMOKING; SYSTEMATIC REVIEW; ULTRAFILTRATION; ACUTE DISEASE; CANADA; CHRONIC DISEASE; CONFERENCE PAPER; FORWARD HEART FAILURE; HEALTH CARE PLANNING;

ACUTE DISEASE; BIOLOGICAL MARKERS; CANADA; CARDIAC OUTPUT, LOW; CHRONIC DISEASE; COMORBIDITY; EVIDENCE-BASED MEDICINE; HEALTH PRIORITIES; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PRACTICE GUIDELINES; RISK FACTORS;

EID: 33847702916     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(07)70211-8     Document Type: Article

References (239)

1. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Can J Cardiol 2006;22:23-45.
2. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005;47:320-32.
3. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9.
4. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9.
5. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006;296:2209-16.
6. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) Study. Eur Heart J 2006;27:2338-45.
7. Yusuf S, Pfeffer MA, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777-81.
8. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006;27:178-86.
9. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25.
10. Dobre D, van Veldhuisen DJ, Dejongste MJ, et al. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 2006. (In press)
11. Feldman AM, Silver MA, Francis GS, et al. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1198-205.
12. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91. (Erratum in 1992;327:1768).
13. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: A follow-up study. Lancet 2003;361:1843-8.
14. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
15. Bell DS. Heart failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26:2433-41.
16. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 2003;362:1527-35.
17. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 1974;34:29-34.
18. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001;22:228-236.
19. Thomas KL, Velazquez EJ. Therapies to prevent heart failure post-myocardial infarction. Current Heart Fail Rep 2005;2:174-82.
20. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
21. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90:1731-8.
22. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996-1002.
23. Johansson S, Wallander MA, Ruigomez A, Garcia Rodriguez LA. Incidence of newly diagnosed heart failure in UK general practice. Eur J Heart Fail 2001;3:225-31.
24. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: An update. Diabetes Care 2004;27:1879-84.
25. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: Observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. Diabetes Care 2003;26:855-60. (Erratum in 2003;26:2489).
26. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with microvascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12.
27. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668-73.
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. (Erratum in 1999;354:602).
29. Canadian Diabetes Association. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):S21-S23.
30. Eriksson H, Svardsudd K, Larsson B, et al. Risk factors for heart failure in the general population: The study of men born in 1913. Eur Heart J 1989;10:647-56.
31. Khush KK, Waters DD. Effects of statin therapy on the development and progression of heart failure: Mechanisms and clinical trials. J Card Fail 2006;12:664-74.
32. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997;3:249-54. (Erratum in 1998;4:367).
33. Aronow WS, Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol 2002;90:147-9.
34. McPherson R, Frohlich J, Fodor G, Genest J. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-27. (Erratum in 2006;22:1077).
35. National Institutes of Health. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel: Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). (Version current at December 19, 2006).
36. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993;22(Suppl A):6A-13A.
37. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure among women with coronary disease. Circulation 2004;110:1424-30.
38. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction in essential hypertension: Prevalence, determinants and prognostic value. Hypertension 2005;45:412-8.
39. Mamun AA, Peeters A, Barendregt J, Willekens F, Nusselder W, Bonneux L; NEDCOM, The Netherlands Epidermiology and Demography Compression of Morbidity Research Group. Smoking decreases the duration of life lived with and without cardiovascular disease: A life course analysis of the Framingham Heart Study. Eur Heart J 2004;25:409-15.
40. Rosen BD, Saad MF, Shea S, et al. Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic individuals: The multi-ethnic study of atherosclerosis. J Am Coll Cardiol 2006;47:1150-8.
41. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 2001;37:1677-82.
42. Tjepkema M. Adult obesity in Canada: Measured height and weight. (Version current at December 19, 2006).
43. Nicklas BJ, Cesari M, Penninx BW, et al. Abdominal obesity is an independent risk factor for chronic heart failure in older people. J Am Geriatr Soc 2006;54:413-20.
44. Kenchaiah S, Gaziano JM, Vasan RS. Impact of obesity on the risk of heart failure and survival after the onset of heart failure. Med Clin North Am 2004;88:1273-94.
45. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-13.
46. Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995;76:1194-7.
47. Alpert MA, Terry BE, Mulekar M, et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol 1997;80:736-40.
48. Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2 004;110:3081-7.
49. Alpert MA, Lambert CR, Terry BE, et al. Effect of weight loss on left ventricular diastolic filling in morbid obesity. Am J Cardiol 1995;76:1198-201.
50. Gahtan V, Goode SE, Kurto HZ, Schocken DD, Powers P, Rosemurgy AS. Body composition and source of weight loss after bariatric surgery. Obes Surg 1997;7:184-8.
51. Zuber M, Kaeslin T, Studer T, Erne P. Weight loss of 146 kg with diet and reversal of severe congestive heart failure in a young, morbidly obese patient. Am J Cardiol 1999;84:955-6.
52. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
53. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9. (Erratum in 2000;356:860).
54. Arnold JM, Yusuf S, Young J, et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003;107:1284-90.
55. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-16.
56. Wang TJ, Levy D, Benjamin EJ, Vasan RS. The epidemiology of "asymptomatic" left ventricular systolic dysfunction: Implications for screening. Ann Intern Med 2003;138:907-16.
57. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003;24:320-8.
58. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
59. Latour-Perez J, Coves-Orts FJ, Abad-Terrado C, Abraira V, Zamora J. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: A systematic review. Eur J Heart Fail 2006;8:390-9.
60. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
61. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: Results from the Dallas Heart Study. Circulation 2005;112:2163-8.
62. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: A community-based study. Circulation 2004;109:3176-81.
63. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The cardiovascular health study. J Am Coll Cardiol 2001;37:1042-8.
64. Nielsen OW, Hansen JF, Hilden J, Larsen CT, Svanegaard J. Risk assessment of left ventricular systolic dysfunction in primary care: Cross sectional study evaluating a range of diagnostic tests. BMJ 2000;320:220-4.
65. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study. JAMA 2002;288:1252-9.
66. McKelvie RS, Benedict CR, Yusuf S. Evidence-based cardiology: Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction. BMJ 1999;318:1400-2.
67. Devereux RB, Bella JN, Palmieri V, et al. Left ventricular systolic dysfunction in a biracial sample of hypertensive adults: The Hypertension Genetic Epidemiology Network (HyperGEN) Study. Hypertension 2001;38:417-23.
68. Devereux RB, Roman MJ, Paranicas M, et al. A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: The Strong Heart Study. Am Heart J 2001;141:439-46.
69. Morgan S, Smith H, Simpson I, et al. Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: Cross sectional survey. BMJ 1999;318:368-72.
70. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: The Framingham heart study. Circulation 2002;106:3068-72.
71. Howlett JG, Johnstone DE, Sketris I, O'Reilly M, Horne GS, Cox JL. Identifying opportunities to address the congestive heart failure burden: The Improving Cardiovascular Outcomes in Nova Scotia (ICONS) study. Can J Cardiol 2003;19:439-44.
72. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005;173:489-95.
73. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the Confusion Assessment Method: a new method for detection of delirium. Ann Intern Med 1990;113:941-8.
74. McKusker J, Cole M, Bellavance F, et al. Reliability and validity of a new mesure of severity of delirium. Int Psychogeriatr 1998;10:421-33.
75. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006;37:2220-41.
76. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-9.
77. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-51.
78. Masoudi FA, Inzucchi SE, Wang Y, Havranck EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation 2005;111:583-90.
79. Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003;290:81-5.
80. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-89.
81. Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62.
82. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
83. McCullough PA. Cardiorenal risk: An important clinical intersection. Rev Cardiovasc Med 2002;3:71-6.
84. Heywood JT. The cardiorenal syndrome: Lessons from the ADHERE database and treatment options. Heart Fail Rev 2004;9:195-201.
85. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005;26:11-7.
86. Francis G. Acute decompensated heart failure: The cardiorenal syndrome. Cleve Clin J Med 2006;73(Suppl 2):S8-13.
87. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-7.
88. Merlo J, Broms K, Lindblad U, et al. Association of outpatient utilisation of non-steroidal anti-inflammatory drugs and hospitalised heart failure in the entire Swedish population. Eur J Clin Pharmacol 2001;57:71-5.
89. Stirling C, Houston J, Robertson S, et al. Diarrhoea, vomiting and ACE inhibitors - an important cause of acute renal failure. J Hum Hypertens 2003;17:419-23.
90. Dei Cas L, Metra M, Leier CV. Electrolyte disturbances in chronic heart failure: Metabolic and clinical aspects. Clin Cardiol 1995;18:370-6.
91. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994;128:564-74.
92. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther 1997;62:187-93.
93. Gerlag PG, van Meijel JJ. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med 1988;148:286-91.
94. Kuchar DL, O'Rourke MF. High dose furosemide in refractory cardiac failure. Eur Heart J 1985;6:954-8.
95. Licata G, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: Long-term effects. Am Heart J 2003;145:459-66.
96. Marangoni E, Oddone A, Surian M, et al. Effect of high-dose furosemide in refractory congestive heart failure. Angiology 1990;41:862-8.
97. Mattana J, Patel A, Ilunga C, Singhal PC. Furosemide-albumin complexes in refractory nephrotic syndrome and chronic renal failure. Nephron 1996;73:122-3.
98. Mouallem M, Brif I, Mayan H, Farfel Z. Prolonged therapy by the combination of furosemide and thiazides in refractory heart failure and other fluid retaining conditions. Int J Cardiol 1995;50:89-94.
99. Gulbis BE, Spencer AP. Efficacy and safety of a furosemide continuous infusion following cardiac surgery. Ann Pharmacother 2006;40:1797-803.
100. Paterna S, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2000;2:305-13.
101. Pivac N, Rumboldt Z, Sardelic S, et al. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. Int J Clin Pharmacol Res 1998;18:121-8.
102. Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management: Comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med 1997;25:1969-75.
103. van Meyel JJ, Smits P, Dormans T, Gerlag PG, Russel FG, Gribnau FW. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med 1994;235:329-34.
104. Mehrotra R, Khanna R. Peritoneal ultrafiltration for chronic congestive heart failure: Rationale, evidence. and future. Cardiology 2001;96:177-82.
105. Ramos R, Salem BI, DePawlikowski MP, et al. Outcome predictors of ultrafiltration in patients with refractory congestive heart failure and renal failure. Angiology 1996;47:447-54.
106. Ronco C, Ricci Z, Bellomo R, Bedogni F. Extracorporeal ultrafiltration for the treatment of overhydration and congestive heart failure. Cardiology 2001;96:155-68.
107. Sharma A, Hermann DD, Mehta RL. Clinical benefit and approach of ultrafiltration in acute heart failure. Cardiology 2001;96:144-54.
108. Sheppard R, Panyon J, Pohwani AL, et al. Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure. J Card Fail 2004;10:380-3.
109. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297-303.
110. Akram K, Pearlman BL. Congestive heart failure-related anemia and a role for erythropoietin. Int J Cardiol 2006. (In press)
111. Silverberg DS, Wexler D, Blum M, et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin Nephrol 2002;58(Suppl 1):S37-45.
112. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardiol 2001;37:1775-80.
113. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
114. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
115. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-9.
116. Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004;43:1423-9.
117. Rickli H, Steiner S, Muller K, Hess OM. Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial). Eur J Heart Fail 2004;6:761-8.
118. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: Results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43:1534-41.
119. Alharethi R, Hershberger RE. Beta-blocker use in decompensated heart failure. Curr Heart Fail Rep 2006;3:75-80.
120. Aronson D, Burger AJ. Concomitant beta-blocker therapy is associated with a lower occurrence of ventricular arrhythmias in patients with decompensated heart failure. J Card Fail 2002;8:79-85.
121. Gattis WA, O'Connor CM, Gheorghiade M. The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: Design and implications. Rev Cardiovasc Med 2002;3(Suppl 3):S48-54.
122. Schuchert A. Effects of bisoprolol treatment for chronic heart failure initiated and followed up by primary care physicians. Eur J Heart Fail 2005;7:604-11.
123. Spargias KS, Hall AS, Greenwood DC, Ball SG. Beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: Evidence from the AIRE Study. Heart 1999;81:25-32.
124. Tarantini L, Cioffi G, Opasich C, et al. Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: An effective strategy for the implementation of beta-blockade in heart failure. Ital Heart J 2004;5:441-9.
125. Thattassery E, Gheorghiade M. Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction. Heart Fail Rev 2004;9:107-13.
126. Williams RE. Early initiation of beta blockade in heart failure: Issues and evidence. J Clin Hypertens (Greenwich) 2005;7:520-8.
127. Butler J, Young JB, Abraham WT, et al. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 2006;47:2462-9.
128. Hunt SA, Baker DW, Chin MH, et al; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
129. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: Population based study. BMJ 2005;330:1370.
130. Juhlin T, Bjorkman S, Gunnarsson B, Fyge A, Roth B, Hoglund P. Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. Eur J Heart Fail 2004;6:909-16.
131. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 2004;363:1751-6.
132. Jolobe OM. Evaluation of renal function in elderly heart failure patients on ACE inhibitors. Postgrad Med J 1999;75:275-7.
133. Spieker LE, Ruschitzka FT, Luscher TF, Noll G. The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail 2002;4:403-10.
134. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: A retrospective cohort study. Heart 2002;87:229-34.
135. Hernandez AF, Newby LK, O'Connor CM. Preoperative evaluation for major noncardiac surgery: Focusing on heart failure. Arch Intern Med 2004;164:1729-36.
136. Hernandez AF, Whellan DJ, Stroud S, Sun JL, O'Connor CM, Jollis JG. Outcomes in heart failure patients after major noncardiac surgery. J Am Coll Cardiol 2004;44:1446-53.
137. Devereaux PJ, Goldman L, Yusuf S, Gilbert K, Leslie K, Guyatt GH. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: A review. CMAJ 2005;173:779-88.
138. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003;348:5-14.
139. Eisenberg MJ, London MJ, Leung JM, et al. Monitoring for myocardial ischemia during noncardiac surgery. A technology assessment of transesophageal echocardiography and 12-lead electrocardiography. The Study of Perioperative Ischemia Research Group. JAMA 1992;268:210-6.
140. Adams KF Jr, Fonarow GC, Emerman CL, et al; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16.
141. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003;41:1797-804.
142. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
143. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
144. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
145. Cowie MR, Jourdain P, Maisel A, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710-8.
146. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
147. Naguch SF, Kopelen HA, Zoghbi WA. Feasibility and accuracy of Doppler echocardiographic estimation of pulmonary artery occlusive pressure in the intensive care unit. Am J Cardiol 1995;75:1256-62.
148. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med 1988;148:2013-6.
149. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J 2006;27:2725-36.
150. Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation 1997;96:1165-72.
151. Mueller HS, Chatterjee K, Davis KB, et al. ACC expert consensus document. Present use of bedside right heart catheterization in patients with cardiac disease. American College of Cardiology. J Am Coll Cardiol 1998;32:840-64.
152. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110:378-84.
153. Marik PE. Pulmonary artery catheterization and esophageal doppler monitoring in the ICU. Chest 1999;116:1085-91.
154. Follath F. Do diuretics differ in terms of clinical outcome in congestive heart failure? Eur Heart J 1998;19(Suppl P):P5-8.
155. Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95.
156. Wilson JR, Reichek N, Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981;70:234-9.
157. Johnson W, Omland T, Hall C, et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol 2002;39:1623-9.
158. Gardtman M, Waagstein L, Karlsson T, Herlitz J. Has an intensified treatment in the ambulance of patients with acute severe left heart failure improved the outcome? Eur J Emerg Med 2000;7:15-24.
159. Ducharme A, Doyon O, White M, Rouleau JL, Brophy JM. Impact of care at a multidisciplinary congestive heart failure clinic: A randomized trial. CMAJ 2005;173:40-5.
160. Dormans TP, Gerlag PG, Russel FG, Smits P. Combination diuretic therapy in severe congestive heart failure. Drugs 1998;55:165-72.
161. Kiyingi A, Field MJ, Pawsey CC, Yiannikas J, Lawrence JR, Arter WJ. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990;335:29-31.
162. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993;71:21A-28A.
163. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-93.
164. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47:76-84. (Erratum in 2006;47:1502).
165. Abraham WT, Adams KF, Fonarow GC, et al; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46:57-64.
166. Cuffe MS, Califf RM, Adams KF Jr, et al; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 2002;287:1541-7.
167. Felker GM, Benza RL, Chandler AB, et al; OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: Results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41:997-1003.
168. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999;138:247-53.
169. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-10.
170. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002;287:1531-40.
171. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5.
172. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91. (Erratum in 2005;111:2274).
173. Arnold LM, Crouch MA, Carroll NV, Oinonen MJ. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Pharmacotherapy 2006;26:1078-85.
174. Teerlink JR, McMurray JJ, Bourge RC, et al; VERITAS Investigators. Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005;150:46-53.
175. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003;42:140-7.
176. Teerlink JR, Massie BM, Cleland JGF, Tzivoni D; RITZ-1 Investigators. A double-blind, parallel-group, multi-center, placebo-controlled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure. Circulation 2001;104:II-526. (Abst)
177. O'Connor CM, Gattis WA, Adams KF Jr, et al; Randomized Intravenous Tezosentan Study-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: Results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003;41:1452-7.
178. Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: Randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: A prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003;41:204-10.
179. Ferguson JJ III, Cohen M, Freedman RJ Jr, et al. The current practice of intra-aortic balloon counterpulsation: Results from the Benchmark Registry. J Am Coll Cardiol 2001;38:1456-62.
180. Hoefer D, Ruttmann E, Poelzl G, et al. Outcome evaluation of the bridge-to-bridge concept in patients with cardiogenic shock. Ann Thorac Surg 2006;82:28-33.
181. Magliato KE, Kleisli T, Soukiasian HJ, et al. Biventricular support in patients with profound cardiogenic shock: A single center experience. ASAIO J 2003;49:475-9.
182. Kherani AR, Cheema FH, Oz MC, et al. Implantation of a left ventricular assist device and the hub-and-spoke system in treating acute cardiogenic shock: Who survives? J Thorac Cardiovasc Surg 2003;126:1634-5.
183. Vasan RS. Biomarkers of cardiovascular disease: Molecular basis and practical considerations. Circulation 2006;113:2335-62.
184. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
185. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-8.
186. Cabanes L, Richaud-Thiriez B, Fulla Y, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001;120:2047-50.
187. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215-8.
188. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-21.
189. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106:416-22.
190. Thomas JT, Kelly RF, Thomas SJ, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 2002;112:437-45.
191. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review. Clin Chem 2004;50:33-50.
192. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
193. Moe GW. BNP in the diagnosis and risk stratification of heart failure. Heart Fail Monit 2005;4:116-22.
194. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004;6:301-8.
195. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
196. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004;90:297-303.
197. Nielsen LS, Svanegaard J, Wiggers P, Egeblad H. The yield of a diagnostic hospital dyspnoea clinic for the primary health care section. J Intern Med 2001;250:422-8.
198. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: A randomized, controlled trial. J Am Coll Cardiol 2003;42:1793-800.
199. Krishnaswamy P, Lubien E, Clopton P, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001;111:274-9.
200. Maisel A. B-type natriuretic peptide in the diagnosis and management of congestive heart failure. Cardiol Clin 2001;19:557-71.
201. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002;105:595-601. (Erratum in 2002;106:387).
202. McKie PM, Burnett JC Jr. B-type natriuretic peptide as a biomarker beyond heart failure: Speculations and opportunities. Mayo Clin Proc 2005;80:1029-36.
203. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005;149:744-50.
204. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004;164:2247-52.
205. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47:91-7.
206. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-9.
207. Jourdain P, Funck F, Bellorini M, et al. Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail 2003;5:155-60.
208. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-41.
209. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart failure Trial (Val-HeFT). Circulation 2003;107:1278-83.
210. Berger R, Stanek B, Frey B, et al. B-type natriuretic peptides (BNP and PRO-BNP) predict longterm survival in patients with advanced heart failure treated with atenolol. J Heart Lung Transplant 2001;20:251.
211. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: A pilot study. J Am Coll Cardiol 2001;37:386-91.
212. Fisher C, Berry C, Blue L, Morton JJ, McMurray J. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 2003;89:879-81.
213. Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8.
214. Hartmann F, Packer M, Coats AJ, et al. NT-proBNP in severe chronic heart failure: Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004;6:343-50.
215. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9.
216. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001;37:1781-7.
217. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-43.
218. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44:1328-33.
219. Januzzi JL Jr, Sakhuja R, O'Donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006;166:315-20.
220. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
221. Jourdain P, Funck K, Gueffet P, LeHelloco H, Donal E, Aupetit JF. Benefit of BNP plasma levels for optimising therapy: The Systolic Heart failure Treatment Supported by BNP Multicenter Randomized Trial (STARS-BNP). J Am Coll Cardiol 2005;45:3A. (Abst)
222. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
223. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006;166:1081-7.
224. Bettencourt P. NT-proBNP and BNP: Biomarkers for heart failure management. Eur J Heart Fail 2004;6:359-63.
225. Healey JS, Davies RF, Smith SJ, Davies RA, Ooi DS. Prognostic use of cardiac troponin T and troponin I in patients with heart failure. Can J Cardiol 2003;19:383-6.
226. Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002;89:691-5.
227. La Vecchia L, Mezzena G, Zanolla L, et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000;19:644-52.
228. Pema ER, Macin SM, Parras JI, et al. Cardiac troponin T levels are associated with poor short- and long-term prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J 2002;143:814-20.
229. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001;103:369-74.
230. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis. JAMA 2005;293:572-80.
231. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model. JAMA 2003;290:2581-7.
232. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-10.
233. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 2005;112:1121-7.
234. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study. Lancet 2003;361:1077-83.
235. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004;44:959-66.
236. Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
237. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart failure of the European Society of Cardiology. Eur Heart J 2005;26:384-416.
238. Swedberg K, Cleland J, Dargie H, et al; Task Froce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
239. Pfeffer MA, Greaves SC, Arnold JMO, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997;95:2643-51.